Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).
作者信息
Park Young-Hwan, Sohn Minji, Lim Soo
机构信息
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
出版信息
Diabetes Metab J. 2024 Sep;48(5):1012-1013. doi: 10.4093/dmj.2024.0485. Epub 2024 Sep 1.
Abstract
摘要
相似文献
1
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效和安全性（《糖尿病代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1012-1013. doi: 10.4093/dmj.2024.0485. Epub 2024 Sep 1.
2
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效及安全性（《糖尿病与代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1005-1007. doi: 10.4093/dmj.2024.0417. Epub 2024 Sep 1.
3
Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.恩格列净作为联合疗法在肥胖 2 型糖尿病患者中的疗效和安全性比较。
J Ayub Med Coll Abbottabad. 2021 Apr-Jun;33(2):188-191.
4
Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus.比较恩格列净和西他列汀作为二甲双胍的附加疗法对 2 型糖尿病患者血清中 asparosin 水平和代谢参数的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):9149-9165. doi: 10.1007/s00210-024-03219-z. Epub 2024 Jun 20.
5
Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial.达格列净+西他列汀+二甲双胍与西他列汀+二甲双胍治疗二甲双胍单药治疗控制不佳的2型糖尿病的疗效：一项多中心随机试验
Adv Ther. 2025 Feb;42(2):801-812. doi: 10.1007/s12325-024-03037-y. Epub 2024 Dec 5.
6
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.在初治的 2 型糖尿病患者中，与逐步加用药物相比，二甲双胍、达格列净和沙格列汀三联疗法的疗效和耐受性：一项多中心、随机、104 周、开放标签、活性对照试验（TRIPLE-AXEL 研究）。
Diabetes Obes Metab. 2024 Sep;26(9):3642-3652. doi: 10.1111/dom.15705. Epub 2024 Jun 10.
7
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.恩格列净、西格列汀和二甲双胍的长期安全性及疗效：一项针对2型糖尿病患者的活性对照、平行组、随机、78周开放标签扩展研究。
Diabetes Care. 2013 Dec;36(12):4015-21. doi: 10.2337/dc13-0663. Epub 2013 Nov 1.
8
9
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.一项恩格列净作为 2 型糖尿病患者二甲双胍附加疗法与达格列净比较的 52 周疗效和安全性研究：ENHANCE-M 扩展研究。
Diabetes Obes Metab. 2024 Jun;26(6):2248-2256. doi: 10.1111/dom.15537. Epub 2024 Mar 8.
10
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.11种不同剂量钠-葡萄糖协同转运蛋白2抑制剂用于二甲双胍控制不佳的2型糖尿病患者的疗效和安全性：一项贝叶斯网络荟萃分析
BMJ Open. 2025 Feb 26;15(2):e088687. doi: 10.1136/bmjopen-2024-088687.
本文引用的文献
1
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.在初治的 2 型糖尿病患者中，与逐步加用药物相比，二甲双胍、达格列净和沙格列汀三联疗法的疗效和耐受性：一项多中心、随机、104 周、开放标签、活性对照试验（TRIPLE-AXEL 研究）。
Diabetes Obes Metab. 2024 Sep;26(9):3642-3652. doi: 10.1111/dom.15705. Epub 2024 Jun 10.
2
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients.二甲双胍、西格列汀和恩格列净初始三联治疗药物初治 2 型糖尿病的两年疗效和安全性。
Diabetes Metab J. 2024 Mar;48(2):253-264. doi: 10.4093/dmj.2023.0128. Epub 2024 Jan 26.
3
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.新诊断 2 型糖尿病患者三联疗法与逐步加药疗法的耐久性比较：EDICT 研究 3 年随访结果
Diabetes Care. 2021 Feb;44(2):433-439. doi: 10.2337/dc20-0978. Epub 2020 Dec 3.
4
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.初治的 2 型糖尿病患者中二甲双胍、西格列汀和罗格列酮三联治疗的疗效和安全性：初始三联研究。
BMJ Open Diabetes Res Care. 2020 Jan;8(1). doi: 10.1136/bmjdrc-2019-000807.
5
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.对于新发糖尿病患者，二甲双胍、吡格列酮和艾塞那肽初始联合治疗比序贯加用治疗更有效。2型糖尿病初始联合治疗的疗效和持久性（EDICT）随机试验结果。
Diabetes Obes Metab. 2015 Mar;17(3):268-75. doi: 10.1111/dom.12417. Epub 2015 Jan 7.
Zotero 插件